Last update 24 May 2025

CHT-102

Overview

Basic Info

Drug Type
CAR-T
Synonyms
CHT102 allogeneic CAR T cells(Tianjin Medical University Cancer Institute and Hospital), CHT-102
Target
MSLN
Action
inhibitors
Mechanism
MSLN inhibitors(Mesothelin inhibitors)
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease
Active Indication
Pancreatic CancerAdvanced Malignant Solid NeoplasmMesothelin positive Solid Tumors+ [1]
Inactive Indication-
Originator Organization
Tianjin Medical University Cancer Institute and HospitalTianjin Medical University Cancer Institute and Hospital
Active Organization
Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with CHT-102
NCT06760364
/ RecruitingPhase 1IIT
A Single-Arm, Open-Label, Phase I Study of CHT102 for MSLN-Positive Advanced Pancreatic Cancer
NCT06717022
/ RecruitingNot ApplicableIIT
A Clinical Study of CHT102, a Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) for Mesothelin(MSLN) Positive Advanced Solid Tumors: a Single-arm, Open-label, Dose Escalation and Expansion Clinical Study
100 Clinical Results associated with CHT-102
Login to view more data
100 Translational Medicine associated with CHT-102
Login to view more data
100 Patents (Medical) associated with CHT-102
Login to view more data
100 Deals associated with CHT-102
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pancreatic CancerPhase 1
China
Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.
25 Dec 2024
Advanced Malignant Solid NeoplasmClinical
China
Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.
06 May 2024
Mesothelin positive Solid TumorsClinical
China
Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.
06 May 2024
Metastatic Solid TumorClinical
China
Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd.
06 May 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free